What's new?

Sofinnova Partners closes €445M ($540M) oversubscribed late-stage healthcare crossover fund

The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...

GenSight Biologics Announces Nature Medicine Case Report Showing Visual Recovery after GS030 Optogenetic Treatment

Paris, France, May 25, 2021, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the highly...

Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3

PARIS, France, May 24, 2021 – 6:30 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces positive phase 2b clinical induction and p...

Avantium reaches key commercial milestone for its FDCA flagship plant with commitments for >50% of its output

AMSTERDAM, 7 April 2021, 18:00 hrs CEST – Avantium N.V., a leading technology company in renewable chemistry, announces that it has signed a conditional offtake agreement with Resilux, an international rigid plastic packaging supplier, for the supply of PEF resin from the planned Avantium FDCA flagship plant. This ...

Protera Appoints Novozymes Executive Thomas Videbaek As Chair of the Board of Directors and Non-Executive Board Member

SANTIAGO, CHILE and PARIS, FRANCE / ACCESSWIRE / April 6, 2021 / Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced today it has appointed Novozymes senior executive Thomas Videbaek as Chair of the Board of Directors and non-exe...

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

- QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) - QR-421a observed to be well tolerated with no serious adverse events reported - Two pivotal Phase 2/3 trials are expected to start by the end of ...

Avantium secures new offtake contracts for planned FDCA flagship plant

Final Investment Decision Progress Update   AMSTERDAM, 24 March 2021, 07:00 CET – Avantium N.V., a leading technology company in renewable chemistry, announces that its subsidiary Avantium Renewable Polymers (“Avantium RNP”) has signed two additional conditional offtake agreements for the supply of PEF resin to man...

Inotrem Bolsters Leadership Team With the Appointment of Sven Zimmermann as New CEO

March 24, 2021 03:00 AM Eastern Daylight Time   PARIS--(BUSINESS WIRE)--Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today the appointment of Sven Zimmermann as Chief Executive Officer, effective April 19th, 2021. Sven bri...

Moon Surgical and King’s College London Announce Strategic Partnership to Develop Machine Learning for Computer-Assisted Surgery

King’s College London’s pioneering research in artificial intelligence & data analytics will strengthen Moon Surgical’s innovative Maestro platform Paris, London & San Francisco – March 23rd, 2021. Moon Surgical and King’s College London, School of Biomedical Engineering & Imaging Sciences, today announ...

Calliditas Announces Submission of New Drug Application to U.S. FDA for Nefecon in Patients with Primary IgA Nephropathy

STOCKHOLM, March 15, 2021/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Nefecon, a novel oral formulation targeting down regulation of IgA1 for the trea...

Abivax publishes data of ABX464 induction and long-term maintenance phase 2a ulcerative colitis study in the prestigious journal 'Gastroenterology'

Peer-reviewed article confirms the quality and robustness of clinical data and the good safety and durable efficacy of once daily oral ABX464 in moderate to severe ulcerative colitis (UC) patients Recruitment of subsequent phase 2b induction study in 254 patients with ABX464 in UC completed in December 2020 and top...

1 2 3 4 ... 11